Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

McNeil label study shows understanding of allergy treatment indication, company says.

This article was originally published in The Tan Sheet

Executive Summary

NASALCROM OTC LABELING SUCCESSFULLY COMMUNICATES ALLERGY INDICATION to most of the respondents in a McNeil-sponsored label comprehension study, McNeil Medical Affairs Exec Director Anthony Temple, MD, told the members of the Nonprescription Drugs and Pulmonary-Allergy Drugs Advisory Committees at an Oct. 10 joint meeting in Bethesda, Md. Temple presented the data in support of McNeil's OTC switch application for the Rx nasal solution. The committee recommended approval of OTC Nasalcrom for the treatment and prevention of allergy rhinitis.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS086222

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel